ECE2023 Poster Presentations Reproductive and Developmental Endocrinology (108 abstracts)
Periodic Assessment of Biochemical-Hematological Changes in A Series of Transgender Men After 1 Year of Gender Affirming Therapy
Guillermo Velasco de Cos 1 , Carlos Latorre Mesa 2 , María Teresa García-Unzueta 1 , Luis Vázquez 3 , Maialen Ormazabal Monterrubio 1 , Armando Guerra Ruiz 1 , Ana Moyano Martinez 4 , Gabriela Alexandra Zapata Maldonado 3 & Aurelia Villar Bonet 3
1Hospital Universitario Marqués de Valdecilla, Clinical Biochemistry, Santander, Spain; 2Universidad de Cantabria - Facultad de Medicina, Santander, Spain; 3Hospital Universitario Marqués de Valdecilla, Endocrinology and Nutrition, Santander, Spain; 4Hospital Clínico Universitario de Salamanca, Clinical Biochemistry, Salamanca, Spain
Introduction: During gender affirming therapy in transgender men (TXM), androgens are administered at escalating doses. As therapy progresses, changes in various analytical parameters occur that may be of potential use in establishing a personalised androgen dosage and avoiding deleterious effects of the medication. The aim of our study was to study the evolution of different parameters throughout the course of gender affirming therapy.
Material and methods: The study was conducted in a cohort of 20 TXM. Treatment was initiated with 25 mg/month of IM testosterone cypionate. Every three months the dose was increased by 25, 50 and 150 mg/month until the maximum dose of 250 mg/month is reached after a year. Samples at 3, 6, 9 and 12 months were analysed by spectrophotometric and automated immunoassay techniques on Snibe Maglumi and Siemens Atellica platforms. Friedman’s test and Wilcoxon pairwise comparisons were performed in SPSS25.0.
Results: The most significant results are summarised in the following tables: No significant differences were found for lipid profile, HbA1c, bilirubin, urea, cortisol, insulin, androstenedione, gonadotrophins and oestradiol. While LH, oestradiol and HDL tended to decrease and triglycerides, cholesterol and urea tended to increase, given the sample size, this was not significant. However, we did obtain significance for haematocrit, haemoglobin, FAI, creatinine and both free and total testosterone.
| Creatinine | GGT | ALP | Hematocrit | Haemoglobin | PSA | |
| Significance Friedman test | P<0.001 | P<0.003 | *p=0.036 | P<0.001 | P<0.001 | P=0.010 |
| First time at which differences are found with basal | t0-6: P=0.004 | t0-6:* P=0.035 | t0-9: P=0.010 | t0-3: *P=0.052 | t0-6: P=0.001 | t0-9: *P=0.023 |
| * Non significant with Bonferroni adjustment (P>0.01), although a clear trend can be observed. | ||||||
| Testosterone | Free testosterone | FAI | DHEAS | |
| Significance Friedman test | P<0.001 | P<0.001 | P<0.001 | P=0.024 |
| First time at which differences are found with basal | t0-6: P=0.003 | t0-6: P=0.003 | t0-6: P=0.004 | t0-3: *P=0.033 |
| * Taking into account the Bonferroni adjustment it would not be significant for any time. | ||||
Conclusions: Several of the parameters analysed change as gender affirmation therapy progresses. Haematocrit is the earliest change. The first significant changes occur after 6 months of treatment. It would be of interest to study a cut-off point for each parameter to allow dose adjustment according to the changes found. The study should be completed when a larger number of subjects in our study who are currently in evolution complete one year of therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more